Emerging Nanotechnology in Chronic Respiratory Diseases
- Publisher:
- Springer International Publishing
- Publication Type:
- Chapter
- Citation:
- Nanoformulations in Human Health, 2020, pp. 449-468
- Issue Date:
- 2020
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
A large population, including people of all age groups, is suffering from chronic respiratory diseases worldwide. Asthma, chronic obstructive pulmonary disease, occupational lung diseases, cystic fibrosis, etc. are the most common of these diseases and are noncurable with conventional and currently available therapies. Nanotechnology is emerging as a great therapeutic promise in different spheres including drug delivery systems and is becoming the technology of choice nowadays. The administration of drugs via inhalation helps in avoiding the first-pass metabolism by targeted delivery to the affected site. It has been observed that there is a huge diversity in nanotechnology being used in pulmonary diseases, and thus safety assessment is a challenging as well as important task. The present review focuses on some of the major emerging nanotechnologies for chronic pulmonary diseases and includes some of the latest studies in the field of nanomedicines.
Please use this identifier to cite or link to this item: